texas oncology more breakthroughs. more victories
Some of our cancer centers may have important notifications found on the location page. View More Important Notifications x

Austin Midtown Research & Clinical Trials

Texas Oncology-Austin Midtown participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Texas Oncology-Austin Midtown (Expand)

Biliary Cancer

Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract

A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002) Read Moreabout Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract

Phase: II/III

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

Blood Cancer

Ph2 Sub Mosunetuzumab B-cell malig

AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389) Read Moreabout Ph2 Sub Mosunetuzumab B-cell malig

Phase: II

Brain Cancer

A Phase II, Multicenter, Prospective Study of Sacituzumab Govitecan in Recurrent Glioblastoma

Breast Cancer

Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas

A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101) Read Moreabout Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas

Phase: I/II

Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)

A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301) Read Moreabout Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)

Phase: III

Ph3 HR+/HER2- BC (OVELIA)

A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA) Read Moreabout Ph3 HR+/HER2- BC (OVELIA)

Phase: III

Ph3 HER2+/ER+ BC

A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571) Read Moreabout Ph3 HER2+/ER+ BC

Phase: III

Ph3 Sac Gov Pemb vs PC BC (ASCENT-04)

A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (GS-US-592-6173) Read Moreabout Ph3 Sac Gov Pemb vs PC BC (ASCENT-04)

Phase: III

Ph3 Sac GOv vs PC BC (ASCENT-03)

A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238) Read Moreabout Ph3 Sac GOv vs PC BC (ASCENT-03)

Phase: III

Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001) Read Moreabout Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Phase: III

Ph3 DAto-DXd PD1/PD L1 BC (TROPION Breast02)

D926PC00001: A Phase III Open-label Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02). Read Moreabout Ph3 DAto-DXd PD1/PD L1 BC (TROPION Breast02)

Phase: III

Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)

EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH) Read Moreabout Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)

Phase: III

Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)

GS-US-595-6184: A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD) Read Moreabout Ph3 Saci Govi Pembro vs PC TNBC (ASCENT-05 / OptimICE-RD)

Phase: III

FLEX Registry: Evaluate New Gene Express

MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Read Moreabout FLEX Registry: Evaluate New Gene Express

Cervical Cancer

Ph2 SKB264 + Pembro in Select Solid Tumors

A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06) Read Moreabout Ph2 SKB264 + Pembro in Select Solid Tumors

Phase: II

Colon Cancer

Ph1b AMG 510 MVASI Combo KRAS CRC

20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with MVASI® and FOLFIRI and in Combination with MVASI® and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol M) Read Moreabout Ph1b AMG 510 MVASI Combo KRAS CRC

Phase: I

Ph1b-XL092 Immun Onco mST

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002) Read Moreabout Ph1b-XL092 Immun Onco mST

Phase: I

Ph2 RO7198457 CRC ctDNA+ Post Resection

A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01) Read Moreabout Ph2 RO7198457 CRC ctDNA+ Post Resection

Phase: II/III

Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas

A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101) Read Moreabout Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas

Phase: I/II

Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX

AN OPEN-LABEL MULTICENTER PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED REFRACTORY OR NEWLYDIAGNOSED CANCERS (IGM-8444-001) Read Moreabout Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX

Phase: I

Ph2 Epidemi Colon Cancer

Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001) Read Moreabout Ph2 Epidemi Colon Cancer

Phase: II/III

Esophageal Cancer

Ph1b/3 Bema + Nivo Gastric GEJ FGFR2b

(20210098) A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102) Read Moreabout Ph1b/3 Bema + Nivo Gastric GEJ FGFR2b

Phase: III

Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas

A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101) Read Moreabout Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas

Phase: I/II

Fallopian Tube Cancer

STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

Phase: II

Gall Bladder Cancer

Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract

A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002) Read Moreabout Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract

Phase: II/III

Gastric Cancer

Ph1b/3 Bema + Nivo Gastric GEJ FGFR2b

(20210098) A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102) Read Moreabout Ph1b/3 Bema + Nivo Gastric GEJ FGFR2b

Phase: III

Head and Neck Cancer

Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas

A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101) Read Moreabout Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas

Phase: I/II

Hematologic

PH2 Brentux+CHP In Tx Naive PTCL

A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032) Read Moreabout PH2 Brentux+CHP In Tx Naive PTCL

Phase: II

Leukemia

PH2 Brentux+CHP In Tx Naive PTCL

A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032) Read Moreabout PH2 Brentux+CHP In Tx Naive PTCL

Phase: II

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II

Ph3b oral asciminib v. nilotinib in newly dx Phl. Chrom+ CML in Chronic phase

A phase IIIb multi-center open-label randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12302) Read Moreabout Ph3b oral asciminib v. nilotinib in newly dx Phl. Chrom+ CML in Chronic phase

Phase: III

Liver Cancer

Ph1b-XL092 Immun Onco mST

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002) Read Moreabout Ph1b-XL092 Immun Onco mST

Phase: I

Lung Cancer

Ph1b AMG 510 in Combo NSCLC KRAS p.G12C

20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Carboplatin and Pemetrexed; with Docetaxel; or with Carboplatin and Paclitaxel in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol F) Read Moreabout Ph1b AMG 510 in Combo NSCLC KRAS p.G12C

Phase: I

STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR

A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004 Read Moreabout STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR

Phase: III

STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203) Read Moreabout STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

Phase: I/II

Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas

A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101) Read Moreabout Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas

Phase: I/II

Ph2 Platform Substudy-01: patients w/ no prior systemic treatment for metastatic NSCLC

A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) Substudy-01: Patients With No Prior Systemic Treatment for Metastatic NSCLC (GS-US-624-6376-01) Read Moreabout Ph2 Platform Substudy-01: patients w/ no prior systemic treatment for metastatic NSCLC

Phase: II

Ph2 Bren Vedo + Pembro ST prior PD-1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033) Read Moreabout Ph2 Bren Vedo + Pembro ST prior PD-1

Phase: II

Ph2 MRTX849 Pembro NSCLC KRAS

A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007) Read Moreabout Ph2 MRTX849 Pembro NSCLC KRAS

Phase: II/III

STAR: PH1/3 Biomarker unresectable stg3 NSCLC

A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777) Read Moreabout STAR: PH1/3 Biomarker unresectable stg3 NSCLC

Phase: III

STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX) Read Moreabout STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

Phase: III

Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)

A Randomized Controlled Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous NSCLC (HARMONi-3)(SMT112-3003) Read Moreabout Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)

Phase: III

Ph3 Study of AK112 or Placebo + Pemtrexed & Carboplatin EGFR NSCLC

A Randomized Double-blind Multi-center Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi) (AK112-301) Read Moreabout Ph3 Study of AK112 or Placebo + Pemtrexed & Carboplatin EGFR NSCLC

Phase: III

Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor

A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216) Read Moreabout Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor

Phase: III

Ph3 SGN-B6A vs docetaxel NSCLC

A randomized phase 3 open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer (SGN-B6A-002) Read Moreabout Ph3 SGN-B6A vs docetaxel NSCLC

Phase: III

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4)

D9103C00001: A Phase III Randomized Placebo-controlled Double-blind Multi-center International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Read Moreabout Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4)

Phase: III

Biomarker status NSCLC

MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361) Read Moreabout Biomarker status NSCLC

Lymphomas

PH2 Brentux+CHP In Tx Naive PTCL

A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032) Read Moreabout PH2 Brentux+CHP In Tx Naive PTCL

Phase: II

Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas

A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101) Read Moreabout Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas

Phase: I/II

Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph

A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302) Read Moreabout Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph

Phase: I

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II

Ph2 Epco r/r B-Cell Lymph out pt

A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting (M23-362) Read Moreabout Ph2 Epco r/r B-Cell Lymph out pt

Phase: II

Ph2 Sub Mosunetuzumab B-cell malig

AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389) Read Moreabout Ph2 Sub Mosunetuzumab B-cell malig

Phase: II

Melanoma

Ph2 Bren Vedo + Pembro ST prior PD-1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033) Read Moreabout Ph2 Bren Vedo + Pembro ST prior PD-1

Phase: II

Myelomas

Ph2 Dara Lena Dexa (DRd) MM I

A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285) Read Moreabout Ph2 Dara Lena Dexa (DRd) MM I

Phase: II

Ovarian Cancer

Ph2 SKB264 + Pembro in Select Solid Tumors

A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06) Read Moreabout Ph2 SKB264 + Pembro in Select Solid Tumors

Phase: II

STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

Phase: II

Pancreatic Cancer

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

Peritoneal Cancer

STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

Phase: II

Prostate Cancer

Ph1b-XL092 Immun Onco mST

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002) Read Moreabout Ph1b-XL092 Immun Onco mST

Phase: I

Ph2 SKB264 + Pembro in Select Solid Tumors

A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06) Read Moreabout Ph2 SKB264 + Pembro in Select Solid Tumors

Phase: II

Ph3 Apalutamide Monotherapy Castration-Sensitive Prostate Cancer (mCSPC) LIBERTAS

A Phase 3 Open-label Randomized Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (56021927PCR3020) Read Moreabout Ph3 Apalutamide Monotherapy Castration-Sensitive Prostate Cancer (mCSPC) LIBERTAS

Phase: III

PH3 Place Capi+ Doce Place+ Doce mCRPC

A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001) Read Moreabout PH3 Place Capi+ Doce Place+ Doce mCRPC

Phase: III

Rectal Cancer

Ph1b-XL092 Immun Onco mST

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002) Read Moreabout Ph1b-XL092 Immun Onco mST

Phase: I

Ph2 RO7198457 CRC ctDNA+ Post Resection

A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01) Read Moreabout Ph2 RO7198457 CRC ctDNA+ Post Resection

Phase: II/III

Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX

AN OPEN-LABEL MULTICENTER PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED REFRACTORY OR NEWLYDIAGNOSED CANCERS (IGM-8444-001) Read Moreabout Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX

Phase: I

Ph2 Epidemi Colon Cancer

Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001) Read Moreabout Ph2 Epidemi Colon Cancer

Phase: II/III

Renal Cancer

Ph1b-XL092 Immun Onco mST

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002) Read Moreabout Ph1b-XL092 Immun Onco mST

Phase: I

Skin Cancer

Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas

A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101) Read Moreabout Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas

Phase: I/II

Solid Tumors

Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C

20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and Chemotherapy in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H) Read Moreabout Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C

Phase: I

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read Moreabout STAR Ph1/2 MRTX849 Solids KRAS G12C

Phase: I/II

STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007) Read Moreabout STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes

Phase: II

Ph2 Bren Vedo + Pembro ST prior PD-1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033) Read Moreabout Ph2 Bren Vedo + Pembro ST prior PD-1

Phase: II

Ph2 Tumor-Agnostic Precision TAPISTRY

TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932) Read Moreabout Ph2 Tumor-Agnostic Precision TAPISTRY

Phase: II

Urothelial Cancer

Ph2 SKB264 + Pembro in Select Solid Tumors

A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06) Read Moreabout Ph2 SKB264 + Pembro in Select Solid Tumors

Phase: II

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

Waldenström macroglobulinemia

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II